TrialTargeted oncology2023

A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.

Naoki Izawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.